Orogen Royalties Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 31
- Registration Number
- NCT05789576
- Locations
- 🇺🇸
Dermavant Investigative Site, Arlington, Texas, United States
🇺🇸Dermavant Investigative Sites, Rockville, Maryland, United States
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: Atozet 10/40 mg or 10/80 mg
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 137
- Registration Number
- NCT05761444
- Locations
- 🇰🇷
Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of
🇰🇷Inje University Ilsan-Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 34
- Registration Number
- NCT05680740
- Locations
- 🇺🇸
Dermavant Investigative Site, Webster, Texas, United States
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 354
- Registration Number
- NCT05560646
- Locations
- 🇺🇸
Central Research Associates LLC dba Flourish Research, Birmingham, Alabama, United States
🇺🇸UAB Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸Olympia Clinical Trials, Los Angeles, California, United States
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
- Conditions
- Contraception
- Interventions
- Drug: NOMAC-E2 COC
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2007
- Registration Number
- NCT05264506
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸SEC Clinical Research, Dothan, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 100
- Registration Number
- NCT05172726
- Locations
- 🇨🇦
Clinical Site, Montréal, Quebec, Canada
🇨🇦Clinical Trials, Oshawa, Ontario, Canada
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
- Conditions
- Contraception
- Interventions
- Combination Product: Radiopaque Etonogestrel (ENG) Implant
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 498
- Registration Number
- NCT04626596
- Locations
- 🇺🇸
Alabama Clinical Therapeutics (Site 0222), Birmingham, Alabama, United States
🇺🇸Desert Star Family Planning (Site 0193), Phoenix, Arizona, United States
🇺🇸Precision Trials (Site 0187), Phoenix, Arizona, United States
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 763
- Registration Number
- NCT04053387
- Locations
- 🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada
🇨🇦Dermavant Clinical Site, Markham, Ontario, Canada
🇺🇸Dermavant Investigational Site, Detroit, Michigan, United States
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 21
- Registration Number
- NCT04042103
- Locations
- 🇺🇸
Dermavant Investigational Site, Spokane, Washington, United States
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 515
- Registration Number
- NCT03983980
- Locations
- 🇨🇦
Dermavant Investigative Site, Ottawa, Ontario, Canada